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Abstract 
PRESENILIN1 (PSEN1) is the major locus for mutations causing familial Alzheimer’s 
disease (FAD) and is also mutated in Pick’s disease of brain, familial acne inversa and dilated 
cardiomyopathy. It is a critical facilitator of Notch signalling and many other signalling 
pathways and protein cleavage events including production of the Amyloidβ (Aβ) peptide 
from the AMYLOID BETA A4 PRECURSOR PROTEIN (APP). We previously reported 
that interference with splicing of the zebrafish orthologue of PSEN1 creates dominant 
negative effects on Notch signalling. Here we extend this work to show that various 
truncations of human PSEN1 (or zebrafish Psen1) protein have starkly differential effects on 
Notch signalling and cleavage of zebrafish Appa (a paralogue of human APP). Different 
truncations can suppress or stimulate Notch signalling but not Appa cleavage and vice versa. 
The G183V mutation possibly causing Pick disease causes production of aberrant transcripts 
truncating the open reading frame after exon 5 sequence. We show that the truncated protein 
potentially translated from these transcripts avidly incorporates into very stable Psen1-
dependent higher molecular weight complexes and suppresses cleavage of Appa but not 
Notch signalling. In contrast, the truncated protein potentially produced by the P242LfsX11 
acne inversa mutation has no effect on Appa cleavage but, unexpectedly, enhances Notch 
signalling. Our results suggest novel hypotheses for the pathological mechanisms underlying 
these diseases and illustrate the importance of investigating the function of dominant 
mutations at physiologically-relevant expression levels and in the normally heterozygous 
state in which they cause human disease rather than in isolation from healthy alleles.
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Introduction 
The human PRESENILIN proteins, PSEN1 and PSEN2, form the central components of -
secretase complexes that are required for the intra-membrane cleavage of over 70 different 
substrates including the APP protein from which the Aβ peptide is derived (1). Aggregates of 
Aβ peptide are the major component of the neuritic plaques that are diagnostic of 
Alzheimer’s disease (AD). Activation of -secretase activity appears to require the 
autoproteolytic cleavage of PRESENILIN proteins followed by association of the resulting 
N- and C-terminal fragments within -secretase complexes (2). These complexes consist 
additionally of the proteins NICASTRIN, PSENEN and APH1A or APH1B (reviewed by 
(3)). Alternatively, a variety of evidence supports that PSEN1 plays an important role in 
macroautophagy (4). Lee and colleagues have shown data supporting that an effect of PSEN1 
on autophagy is via a -secretase-independent role of the PSEN1 holoprotein in acidification 
of lysosomes (4). However, other published data conflict with this (5, 6). The possibility 
exists that dysfunctional autophagy due to mutations in PSEN1 may contribute to inherited 
(familial) AD (FAD) although this is currently debated (see (7) and resulting 
correspondence). 
Over a decade of research has focussed on the role of mutations in the PRESENILINS in 
altering the -secretase cleavage of APP to support varieties of Aβ peptide. Much of this 
work has been conducted in cultured cells such as HEK293 cells and using cell-free assays 
where -secretase is solublised using the non-denaturing detergent CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate, (8)). Currently, the dominant idea 
is that FAD mutations promote the formation of more aggregation-prone forms of Aβ such as 
the 42 amino acid residue (aa) form relative to the more common (and possibly protective 
(9)) 40 aa form. This supposedly occurs in endosomes and at the plasma membrane (10, 11). 
However, recent discoveries raise caveats over these ideas. Winkler et al. (12) have shown 
that the thickness of the lipid bilayer (affected by its lipid makeup) can influence the site of -
secretase cleavage of APP and so alter Aβ size. Since cell-free assays involve solubilisation 
of the -secretase complex, this must change the lipid environment of -secretase and so 
probably affects Aβ product size. Also, Area-Gomez et al (13) showed in an elegant paper in 
2009 that, in mouse brain, the majority of Psen1 protein, all detectable Psen2 protein, and 
most -secretase activity resides in a detergent-impermeable lipid-raft like region of the 
endoplasmic reticulum named the mitochondrial associated membranes (MAM). The 
implications of this revision of our understanding of the subcellular distribution of 
PRESENILIN protein and -secretase activity have not yet been examined. 
The gene PSEN1 is the major locus for mutations causing FAD. Interestingly, all of the more 
than 180 different mutations in PSEN1 known to cause FAD allow retention of the C-
terminal sequence of the protein. This – and the absence of FAD mutations in other 
components of -secretase complexes – is consistent with involvement of an autophagy 
function of the PSEN1 holoprotein in AD pathology. The only disease-causing mutation of 
PSEN1 involving simple truncation of the open reading frame (rather than partial interference 
with splicing resulting in multiple transcript isoforms) is the P242LfsX11 mutation causing 
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the inherited skin disease familial acne inversa (FAI) (14). P242LfsX11 causes a frameshift 
in exon 7 resulting in a premature termination codon. This mutation causes decreased PSEN1 
transcript levels in lymphocytes (14) probably due to nonsense mediated decay (NMD) of 
transcripts of the mutant allele. Nevertheless, the mutant transcript can still be detected 
implying that low levels of truncated PSEN1 protein may be produced. Similarly, the G183V 
mutation that may cause Pick disease of brain affects the splice donor site of exon 6 
producing a transcript encoding a full-length protein with a missense mutation (G183V, (15)) 
and also transcripts lacking either sequence from exon 6 or exons 6 and 7 (16). These 
transcripts would have frameshifted open reading frames putatively encoding proteins 
prematurely truncated after exon 5 sequence. Interestingly, in a mouse knock-in model of this 
mutation, Watanabe et al. (17) observed aberrantly splicing of PSEN1 only in brain. The 
aberrant transcripts are subject to NMD but can, nevertheless, be detected.  When transfected 
into cultured HEK293 cells or into MEF cells lacking endogenous PRESENILINS, the 
G183V full length transcript itself gave only mild effects on Aβ production (15) or no effects 
on Notch cleavage (17) respectively. This is consistent with the lack of AD pathology seen 
for G183V. Watanabe et al. suggest that the Pick disease possibly resulting from G183V may 
be due to decreased overall -secretase activity but this contrasts with the observations of 
Wang et al. (14) where the P242LfsX11 FAI mutation also reduced PSEN1 levels but was not 
reported to produce Pick disease (and did not appear to cause FAD). 
Another change in PRESENILIN gene splicing associated with human disease is exclusion of 
exon 5 sequence from transcripts of PSEN2 in the brains of people with sporadic, late onset 
AD (18, 19). This produces a truncated isoform of the PSEN2 protein, PS2V. Interestingly, 
this isoform can stimulate APP cleavage and Aβ production when expressed in mouse Neuro 
2a cells (20). We have also recently shown the PS2V transcript to be up-regulated in guinea 
pig brain under conditions of hypoxia and cholesterol loading (21).  Up-regulation of this 
transcript was associated with cholesterol-enhanced amyloidogenic processing of APP. 
In mammals, PSEN1 protein is essential for Notch signalling since it is required for cleavage 
of Notch receptors within their single transmembrane domains after their extracellular 
domains are removed as a consequence of binding extracellular ligands. PSEN1-controlled -
secretase activity releases the Notch intracellular domain (NICD) that subsequently enters the 
nucleus to regulate gene activity. Notch signalling is essential for maintaining stem cells in an 
undifferentiated state (22), for controlling cell fate decisions (reviewed by e.g. (23-26)) and is 
commonly dysregulated in cancer (27). Changes in Notch signalling have been suggested to 
underlie FAI pathology (14) and this is supported by the discovery of additional mutations 
causing FAI in other components of -secretase complexes (in contrast to FAD) (14).  
Rates of aberrant splicing have been seen to increase in ageing and cancerous cells (reviewed 
in (28, 29)). Aberrant splicing of PSEN1 in particular was observed in sporadic 
frontotemporal dementia ((30), of which Pick’s disease of brain is one type). While NMD 
plays an essential role in the elimination of transcripts encoding aberrantly truncated proteins 
it can be incompletely effective under certain circumstances, e.g. when a premature 
termination codon occurs within 55 bp of a downstream exon-exon junction (31). The 
modular nature of many proteins where separate domains have separate activities means that 
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it is common for truncated proteins to possess a subset of their normal activities. This allows 
them to interfere dominantly with the function of normal full-length proteins. Thus it is 
important to consider the activities of the potential protein products of aberrant transcripts 
whenever detection of such transcripts suggests that truncated proteins may exist.  
Zebrafish embryos are an excellent system in which to analyse cellular responses to changes 
in gene expression. Unlike cells grown in culture, the cells of zebrafish embryos exist in an 
environment of normal substrates and cell-cell interactions. Simultaneous and subtle up-
regulation and down-regulation of gene expression is possible at levels consistent with 
normal cell physiology. In previous work we attempted to use the unique advantages of the 
zebrafish system to model particular rare FAD mutations in PSEN1 where protein coding 
exons are excluded but the reading frame is maintained. We did this by blocking splice 
acceptor sites in the zebrafish orthologue of PSEN1 (named psen1) using morpholino 
antisense oligonucleotides (“morpholinos”). Unexpectedly we generated low levels of intron 
inclusion rather than exon exclusion but some of the aberrant transcripts nevertheless had 
potently dominant negative effects on the activity of both psen1 and the zebrafish orthologue 
of PSEN2 (named psen2) (32). 
In the work described in this paper we confirm the predominant MAM-localisation of PSEN1 
protein in mammalian (mouse) brain. We then use our zebrafish embryo-based in vivo assays 
of Notch signalling and APP cleavage to expand our previous study of the -secretase activity 
of PSEN1 truncations including PSEN1 truncations relevant to human diseases other than 
AD. We show that, at physiologically relevant levels, different truncations of PSEN1 can 
have starkly contrasting effects on zebrafish Notch signalling and Appa cleavage. 
Truncations resembling PS2V boost both Notch and Appa cleavage in a manner dependent 
on the presence of endogenous zebrafish Psen1 protein but not Psen2 protein. Truncations 
equivalent to some of the products of the G183V Pick disease mutation reduce Appa cleavage 
but do not affect Notch. They also bind full-length endogenous Psen1 and Psen2 and 
integrate into higher molecular weight complexes. In contrast, the truncation produced by the 
P242LfsX11 acne inversa mutation unexpectedly increases Notch signalling with no effect on 
Appa cleavage. Our discoveries imply that in vivo analysis of -secretase activity may give 
more realistic insights into the role of -secretase activity in human disease. Our observations 
also suggest transgenic approaches to allow manipulation of Notch signalling without 
affecting APP cleavage and vice versa. 
 
Results 
PSEN1 protein is concentrated in the MAM in brain 
The majority of FAD is due to mutations in the genes encoding the human proteins PSEN1 
and PSEN2. In 2009 Area-Gomez et al. demonstrated that, in the mammalian (mouse) brain, 
the greatest concentration of PSEN1 protein, -secretase activity and -secretase cleavage of 
APP is localised to the MAM (13). They also showed that the MAM is difficult to 
permeabilise for immunohistochemistry using standard detergents since it has a lipid 
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constitution similar to that of lipid rafts (13, 33). Also, Winkler et al (12) recently showed 
that changes in the thickness of lipid bilayers can affect the cleavage of APP proteins by -
secretase to produce different forms of A. However, much of the debate on the role of -
secretase activity in AD is based on data obtained from cell-free assays where -secretase 
activity is solubilised using detergents. Such cell-free assays may not entirely reflect the -
secretase activity found in vivo. To confirm independently the controversial MAM-
localisation of PSEN1 protein we replicated the sub-cellular fractionation of mouse brain by 
Area-Gomez et al. (13). As expected, this showed that PSEN1 is predominantly localised to 
the MAM with lower concentrations in the rest of the endoplasmic reticulum and in 
mitochondria (Supplemental Data Figure 1). 
Delimiting the region of Psen1 in which truncation produces dominant negative effects 
on Notch signalling 
In addition to their role in -secretase, PRESENILIN proteins are thought to have multiple 
cellular activities in e.g. phosphorylation of β-catenin (34, 35), Ca2+ transport (36, 37) and 
macroautophagy (4). The involvement of the PRESENILINs in these other activities has not 
been studied in depth and it is unclear to what extent these activities interact with -secretase 
activity. Also, cell-free assays of -secretase activity have been shown to be very sensitive to 
preparation and assay conditions (discussed in (38)). Therefore, analysis of PRESENILIN 
activity in vivo may give a more realistic understanding of their roles in cell biology and 
disease than analysis in cell-free systems. -Secretase activity can be studied using cultured 
cells (such as HEK293 cells) transfected with assay or other constructs (e.g. (39)). However, 
due to their unusual environments, cultured cells commonly have unusual patterns of gene 
and protein expression (40, 41) while high-level expression of genes/proteins through 
transfection can produce physiologically irrelevant results such as the complete abolition of 
endogenous Psen protein by exogenous Psen (42). Fertilized zebrafish eggs represent an 
interesting alternative in vivo system in which to analyse gene activity since their large size 
allows easy, subtle and multifactorial manipulation of gene activity at the 1-cell stage. Also, 
their subsequent development through the various stages of embryogenesis allows changes in 
phenotype to be used as bioassays of changes in gene activity.  
-Secretase activity is required for the intra-membraneous cleavage of Notch receptors that 
facilitates transcriptional regulation of genes by Notch intracellular domains (reviewed by 
(43)). We (32, 44) and others ((45-48)) have previously observed changes in Notch signalling 
in zebrafish embryos by examining changes in the expression of the neurogenin1 gene that is 
a under transcriptional regulation by Notch (45). In previously published work examining 
PRESENILIN’s -secretase activity we monitored spinal cord neurogenin1 transcript levels 
in zebrafish embryos at 24 hours post fertilisation (hpf @28.5 °C) to assess changes in Notch 
signalling. This led to discovery of dominant negative effects on Notch signalling caused by 
interference with splicing of zebrafish psen1 gene transcripts (32). These dominant negative 
effects occur upon interference with splicing to zebrafish psen1 exons cognate with human 
PSEN1 exons 7 and 8 but not 6 or 9. (Hereafter the zebrafish exons are referred to by their 
human cognate numbers, see Figure 1.) Injection into embryos of mRNA encoding zebrafish 
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Psen1 protein truncated after exon 6 (equivalent to the putative product of the aberrant 
transcript produced by interference with splicing to exon 7 (32)) produced a similar dominant 
negative phenotype supporting that this effect is due to the formation of truncated Psen1 
protein molecules. We have subsequently shown that our injection of synthetic mRNA into 
zebrafish embryos gives total mRNA levels less than threefold higher than normal (see 
Supplemental Data Figure 2). Thus, interference with the splicing of endogenous genes and 
injection of synthetic mRNAs causes changes in gene activity in zebrafish embryos at 
physiologically relevant levels. 
Notch signalling is an important component of embryo development, stem cell maintenance 
and human diseases including some cancers. Truncations of the N-terminal fragment (NTF) 
of human PSEN1 feature in a number of human disease states (see the Introduction and 
below). Therefore, we sought to use our zebrafish model to analyse how truncations of the 
NTF in zebrafish Psen1 affect Notch signalling. Since the effects of interference with splicing 
are not entirely predictable we focussed instead on injection of synthetic mRNAs. We 
synthesised mRNAs encoding the entire NTF or forms of Psen1 truncated downstream of 
sequence encoded in exons 3, 4, 5, 6, 7, or 8 (Figure 1). These were injected into zebrafish 
embryos and their effects on neurogenin1 expression in the spinal cord (negatively regulated 
by Notch signalling) were analysed at 24 hpf. Interestingly, we observed both enhancement 
and suppression of Notch signalling. 
Injection of mRNA encoding a truncation of Psen1 after exon 3 sequence (Psen1Δ>3) proved 
quite toxic to embryo survival unlike the other, longer truncations. Therefore, we did not 
analyse this truncation further. Injection of mRNA coding for Psen1 truncated after exon 4 
sequence (Psen1Δ>4) caused significant change in neurogenin1 transcription compared to 
embryos injected with a negative control mRNA (Figure 2A). Surprisingly, Psen1Δ>4 acts in 
a “dominant positive” manner to decrease neurogenin1 transcription, presumably by 
increasing Notch signalling. In contrast, mRNAs encoding Psen1 proteins truncated after 
exon 5, 6, 7, or 8 sequence behaved as expected from our previously published analysis using 
morpholinos (44).  Truncation of Psen1 after exons 5 or 8 (Psen1Δ>5 and Psen1Δ>8) or the 
entire NTF caused no significant change in neurogenin1 transcription relative to embryos 
injected with a negative control mRNA. However, mRNAs encoding Psen1 truncated after 
exons 6 and 7 (Psen1Δ>6 and Psen1Δ>7) caused an increase in neurogenin1 expression 
indicative of decreased Notch signalling (Figure 2A). 
Our results, and those of our previous study using morpholinos ((32)) initially led us to 
believe that the region of psen1 flanked by exons 6 and 8 (i.e. exon 7) encoded a section of 
the Psen1 protein within which any truncation would produce dominant negative effects on 
Notch signalling. However, additional analysis showed this interpretation to be incorrect (see 
later). 
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Truncations of Psen1 produce distinct and overlapping effects on Notch signalling and 
cleavage of zebrafish Appa 
-Secretase cleaves over 70 protein substrates in addition to Notch receptors (reviewed by 
(1)). Among the most important of these for human disease is the AMYLOID PRECURSOR 
PROTEIN, APP. APP is cleaved by -secretase after initial cleavage by –secretase or –
secretase in its N-terminal, luminal/extracellular domain close to the lipid bilayer (49-52). 
Zebrafish possess two paralogous genes, appa and appb, derived from an ancestral 
orthologue of human APP (53). We recently developed a zebrafish assay for -secretase 
cleavage of Appa that monitors cleavage of an Appa substrate truncated to resemble the 
putative 86 aa C-terminal product of β-secretase cleavage (“AppaC86::GFP”, (38)). 
Mutations (54) and drugs (55) affecting Presenilin activity have been reported to have 
differential effects on Notch and APP cleavage. Therefore we exploited our Appa-based 
assay to investigate whether our truncations of Psen1 had similar or different effects on APP 
cleavage compared to Notch signalling. 
Injection of mRNA encoding Psen1Δ>4 caused increased cleavage of Appa similar to the 
effect of this truncation on Notch signalling. However, whereas Psen1Δ>5 had no effect on 
Notch signalling, we found that it acted to inhibit -secretase cleavage of Appa (Figure 3A). 
Futhermore, in contrast to their dominant negative effect on Notch signalling, Psen1Δ>6 and 
Psen1Δ>7 did not affect Appa cleavage. Psen1Δ>8 and the entire NTF did not affect either 
Appa cleavage or Notch signalling in our zebrafish embryo system (Figure 3A). 
To support that our observations were the result of expression of truncated forms of Psen1 at 
physiologically relevant levels we attempted to reproduce the above effects on 
AppaC86::GFP substrate cleavage through directed interference with endogenous psen1 
transcript splicing. Morpholinos that bind over the acceptor sites of exons 5, 7, 8, and 9 exist 
and can interfere with splicing of endogenous psen1 transcripts. These cause retention of the 
respective upstream introns (see Supplemental Data Figure 3) and, presumably, expression of 
transcripts with open reading frames prematurely terminated after exons 4, 6, 7 and 8 
respectively. The assay results from morpholino injection are consistent with those seen for 
mRNA injection (Figure 3C). 
The different effects of particular Psen1 truncations on Notch and Appa are consistent with 
the idea that differently composed -secretase complexes are responsible for Notch and APP 
cleavage (56, 57). Our observations also show that it should be possible to construct 
transgenes that specifically inhibit Notch cleavage but not APP cleavage and vice versa. 
Alternatively Psen1Δ>4 can be used to boost both Notch signalling and APP cleavage in 
cells, tissues and transgenic animals. 
Psen1Δ>4 requires endogenous, normal Psen1, but not Psen2 to increase -secretase 
activity 
Psen1Δ>4 is structurally equivalent to the “PS2V” isoform of human PSEN2 that is induced 
in neurons by hypoxia and is found at increased levels in the brains of people with sporadic, 
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late onset AD. Consistent with our results, PS2V has been shown to increase -secretase 
activity and Aβ levels when its expression is forced in the mouse neuro2a neuroblastoma cell 
line (20). However, Psen1Δ>4 and PS2V do not possess the NTF portion of the putative 
proteolytic site of -secretase that includes a conserved, essential Asparagine residue (Asp 
257 in human PSEN1 or Asp 263 in human PSEN2). Truncations Psen1Δ>4, Δ>5, Δ>6, and 
Δ>7 also lack this residue and so would be incapable themselves of contributing directly to -
secretase cleavage. An explanation for the ability of Psen1Δ>4 and PS2V to boost -secretase 
activity is that they are dependent on endogenous, normal Presenilin proteins to do so. 
Zebrafish embryos are a very versatile cellular system in which to dissect molecular 
interactions since it is possible to block and force expression of multiple gene activities 
simultaneously. To test the dependence of Psen1Δ>4 on endogenous Presenilin proteins we 
injected mRNA encoding Psen1Δ>4 while simultaneously blocking translation of either 
endogenous Psen1 or Psen2 using morpholinos (“MoPsen1Tln” and “MoPsen2Tln” 
respectively). Analysis of Notch signalling using the neurogenin1 expression assay was then 
performed by comparing trunk spinal cord neurogenin1 expression in these embryos to that 
in control embryos that had been injected either with negative control (inactive) morpholino 
“MoCont” or with the MoPsen1Tln or MoPsen2Tln morpholinos as appropriate to block 
endogenous Psen1 or Psen2 translation respectively (see Figure 4A). Psen1Δ>4 was unable to 
increase Notch signalling (neurogenin1 expression) significantly in embryos lacking 
endogenous full-length Psen1 (Figure 4A). In contrast, blockage of Psen2 translation could 
not block the ability of Psen1Δ>4 to boost Notch signalling (Figure 4A). This supports that 
Psen1Δ>4 acts through normal Psen1 in order to boost -secretase activity while acting to a 
lesser extent (if at all) through endogenous Psen2.  
Psen1Δ>4 expression also boosts cleavage of Appa (see above). To support that Psen1Δ>4’s 
dependence on endogenous Psen1 also applies for substrates other than Notch we tested its 
ability to cleave AppaC86::GFP in the absence of Psen1 or Psen2 translation. Consistent with 
the results for Notch above, Psen1Δ>4 could only increase AppaC86::GFP cleavage when 
Psen1 was present while blockage of Psen2 translation had no effect on the ability of 
Psen1Δ>4 to increase AppaC86::GFP cleavage (Figure 4B). 
Psen1 truncations incorporate into higher molecular weight complexes 
It is commonly observed that Presenilin proteins are incorporated into higher molecular 
weight (HMW) complexes that are sufficiently stable to withstand the highly denaturing 
conditions involved in protein resolution by SDS-polyacrylamide gel electrophoresis (PAGE, 
e.g. see (58-60)). Kim et al (59) previously showed that forced expression of the NTF of 
human PSEN1 in mouse embryonic fibroblasts (MEFs) resulted in the formation of such 
stable complexes. A simple model for the dominant effects of truncated Psen1 on Notch 
signalling and Appa cleavage is that this occurs by interference with formation of -secretase 
complexes. Our various truncated forms of zebrafish Psen1 have been tagged at their N-
termini using the FLAG antibody tag. To observe whether the Psen1 truncations could 
incorporate into HMW complexes we expressed them in zebrafish embryos and then 
subjected embryo lysates to SDS-PAGE followed by western blotting against the FLAG tag 
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(Figure 5A). This revealed apparent complexes in the range of 50-250 kDa while few protein 
bands in the predicted monomer range of ~15-30 kDa were observed. In particular, 
truncations Psen1Δ>5, Δ>7, Δ>8 and NTF avidly incorporated into apparent SDS-resistant 
complexes of approximately 200 kDa or greater (Figure 5A). However, it is known that 
forced over-expression of proteins in cells can lead to the formation of non-specific SDS-
resistant aggregates (e.g. (61)). Since our analysis of Psen1Δ>4 has shown that its activity is 
dependent on the presence of endogenous Psen1 (see above) we sought to demonstrate that 
the Psen1 truncations were being incorporated into HMW complexes relevant to endogenous 
Psen1 activity. We analysed the incorporation of the truncations into SDS-resistant 
complexes with and without blockage of translation of endogenous Psen1 (Figure 5A). 
Distinct differences in complex formation were observed for truncations Psen1Δ>5, Δ>7, 
Δ>8 and NTF when these were expressed with or without endogenous Psen1. Apparently, the 
loss of endogenous Psen1 enhances the incorporation of the truncated Psen1 molecules into 
HMW complexes. This supports that the complex formation observed is specific and related, 
in some way, to Psen1 activity (although not necessarily γ-secretase activity). 
As an additional test that our truncated Psen1 proteins can interact with endogenous, normal 
Psen1 protein we performed immuno-precipitation analysis under non-denaturing conditions 
using ANTI-FLAG M2 Affinity Gel on embryos injected with mRNA coding for either the 
most avid apparent interactor Psen1Δ>5 or (as a negative control) a form of GFP tagged at its 
N-terminal with FLAG. Immunoblotting of the lysates and precipitates clearly demonstrated 
a specific interaction of Psen1Δ>5 with Psen1 and, interestingly, also with endogenous Psen2 
while GFP failed to interact with either endogenous protein (Figure 5B). This suggests that 
immuno-precipitation of our FLAG-tagged Psen1 truncations under non-denaturing 
conditions should co-precipitate interacting proteins and permit their identification by 
proteomics methods. 
Remarkably, loss of endogenous Psen1 apparently causes increased incorporation of 
Psen1Δ>5 into the very largest HMW complexes but a dramatic decrease in the incorporation 
of this truncation into an ~50 kDa complex with a concomitant increase in levels of a smaller 
form at ~25 kDa (while the monomer has a theoretical mass of ~17 kDa). A similar behaviour 
is shown by Psen1Δ>8 and these are the two truncations that do not appear to influence 
Notch activity. The behaviour of Psen1Δ>5 is particularly interesting since this is the only 
truncation that inhibited Appa cleavage. This supports that Notch and APP are cleaved by -
secretase activities in distinct complexes. Also, Psen1Δ>5 resembles the putative protein 
products of the abnormal transcripts caused by the G183V mutation of human PSEN1 that 
affects the splice donor site of exon 6. This is the only PSEN1 mutation suggested to cause 
FTD without associated AD pathology. Our analysis suggests that the transcript putatively 
encoding human PSEN1 truncated after exon 5 sequence may suppress APP cleavage and A 
peptide formation consistent with the lack of AD histopathology (A plaques). 
The ~50 kDa complex seen for all the injected truncations (but not Psen1NTF or the negative 
control) does not appear to represent dimer formation since the Psen1Δ>5 truncation and 
larger truncated peptides have monomeric masses in the range of 17-30 kDa. Also, the mass 
of the ~50 kDa complex does not appear to change with the size of the truncation injected. 
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Therefore, we suspect that the ~50 kDa complex represents the protease-resistant core of a 
larger unstable entity that includes part or all of our FLAG-tagged Psen1 truncations. 
Truncations of human PSEN1 produce similar effects to their zebrafish equivalents 
when expressed in zebrafish embryos 
To confirm that our observations using zebrafish embryos are relevant to the human system 
we sought to express truncations of human PSEN1 in the human kidney-derived cell line 
HEK293. Truncations of human PSEN1 after exon 4, 5, 6, 7 and 8 sequence and with N-
terminal HA antibody tags were synthesised in the pcGlobin2 vector that can be used for 
mRNA synthesis or to express genes downstream of a CMV promoter (62). The truncations 
of human PSEN1 were named hPSEN1Δ>4, 5, 6, 7 or 8 to correspond to the zebrafish Psen1 
truncations. Unfortunately, repeated attempts to generate stably transformed cell lines 
expressing the human PSEN1 truncations failed. Apparently, the human PSEN1 truncations 
are too toxic to allow survival and growth of HEK293 cells, possibly because transfection 
gives excessive, non-physiologically relevant levels of expression. Therefore, we generated 
mRNAs encoding each of the human PSEN1 truncations and expressed these in zebrafish 
embryos by mRNA injection. Our assays for Notch signalling (Figure 2B) and Appa cleavage 
(Figure 3B) showed that the human PSEN1 truncations produce effects on these activities 
identical to their zebrafish Psen1 equivalents. This supports that our analysis of Presenilin 
activity in zebrafish is relevant to our understanding of this activity in the human system. 
The P242LfsX11 mutation of human PSEN1 causing acne inversa dominantly increases 
Notch signalling but not Appa cleavage.  
Recently Wang et al (2010) identified that mutations in three of the four protein components 
of the -secretase complex, PSEN1, NICASTRIN and PSENEN, can cause an inherited 
disease of hair follicles named acne inversa (AI). These researchers discovered only one AI 
mutation in PSEN1 - a single base deletion, c.725delC, causing a frameshift that results in the 
premature termination of the open reading frame. The mutant protein structure is denoted as 
P242LfsX11. This is the first known inherited mutation in PSEN1 exclusively causing 
truncation of the open reading frame.  (The FAD mutations of PSEN1 all still allow synthesis 
of mRNAs encoding entire open reading frames.) Unexpectedly, none of the families with 
inherited AI show familial Alzheimer’s disease and Wang et al. 2010 (14) suggested that AI 
may be caused by changes in Notch signalling affecting follicle biology (14). PSEN1 
transcript levels are reduced by varying amounts in heterozygotes suggesting that nonsense 
mediated decay is destroying transcripts possessing the premature termination codon 
generated by this mutation. However, supplemental data published with the Wang et al. paper 
shows that low levels of transcript containing the P242LfsX11 mutation are still observable 
in lymphocytes from affected individuals. However, the P242LfsX11 mutation places a 
premature stop codon within 20 bp upstream of the next downstream exon junction (Figure 
6A). Thus, the mutation potentially lies too close to the exon-exon junction for nonsense 
mediated decay to be completely effective (according to the “50-55 bp rule” (31)). 
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We were surprised to see that P242LfsX11 lies in exon 7 since we believed that truncating 
mutations in this region would have potently dominant negative effects on Notch signalling 
and that even minor levels of the mutant transcript might interfere fatally in embryo 
development – i.e. they would be dominant lethal (32). Therefore, we tested the activity of 
the putative protein product of the P242LfsX11 mutation in our zebrafish system. Construct 
hPSEN1-P242LfsX11 incorporating the P242LfsX11 mutation was generated in the 
pcGlobin2 vector using the human PSEN1 gene and then mRNA was synthesised for 
injection into zebrafish embryos. No effect was observed on Appa cleavage consistent with 
the fact that individuals with this AI mutation do not show early onset FAD (Figure 6B). 
Also, Notch signalling was observed to increase rather than decrease implying that Notch 
signalling in individuals heterozygous for P242LfsX11 may be greater than that expected if 
P242LfsX11 was a simple, loss-of-function mutation (Figure 6C). This discovery also means 
that it should be possible to construct transgenes that boost Notch signalling without 
increasing APP cleavage. 
 
Discussion 
The PRESENILIN proteins are essential to facilitate many signalling pathways and protein 
cleavage events. They modulate intracellular Ca2+ ion levels (36, 37), regulate β-catenin 
turnover (34, 35) and influence autophagy (4). Therefore, changes in PRESENILIN activity 
can have widespread effects on cell function and are associated with numerous human 
diseases.  In earlier work we showed that low levels of truncated zebrafish Presenilin 
molecules can exert potent dominant negative effects on Notch signalling (32). Truncated 
PRESENILIN proteins (or at least aberrantly spliced transcripts) occur either as natural 
isoforms (e.g. PS2V (18)), result from mutation (e.g. FAD (63), acne inversa (14)) or exist in 
particular disease states such as FTD (30). Thus it is important to understand their effects on 
cell biology. 
The discovery of the MAM as the primary subcellular location of the PRESENILIN proteins, 
-secretase activity and -secretase cleavage of APP in neural tissue (13) is revolutionising 
our understanding of the role of PRESENILIN mutations in FAD (33). We have now 
independently confirmed the predominant localisation to the MAM of mammalian Psen1 
protein. The true sub-cellular distribution of the PRESENILINs remained unknown until 
recently due to the MAM’s tight physical association with mitochondria and its peculiar lipid 
raft-like characteristics that prevented its permeabilisation by common 
immunohistochemistry detergents (13, 64). Also, Winkler et al. recently observed that the site 
of -secretase cleavage within APP is affected by the thickness of the lipid bilayer within 
which APP resides (12). This raises the question of how solubilisation of -secretase with 
detergents in cell-free assays affects observations of APP cleavage and the different forms of 
Aβ formed by different PRESENILIN mutants. Interestingly, Area-Gomez et al recently 
showed that changes in PRESENILIN activity affect movement of cholesterol into and out of 
MAM membranes (33). This raises the possibility that changes in the profile of A lengths 
observed in FAD PRESENILIN mutants may be the secondary effect of changes in the lipid 
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constitution of MAM membranes rather than a direct effect of the mutations on the cleavage 
interaction between a PRESENILIN molecule and an APP molecule within the -secretase 
complex itself. Of course, many of the experimental caveats regarding cell-free and cell 
culture approaches to analysis of -secretase would be obviated by the use of in vivo assays. 
Indeed, our in vivo assay for -secretase cleavage of APP (Appa) is unique in this regard. 
In disease states, mutant genes encoding truncated PRESENILIN open reading frames are 
always found concomitantly with wild-type PRESENILIN genes. However, previous analyses 
of truncated PRESENILINs have examined their biochemical activities in backgrounds 
lacking full-length proteins. Thus Laudon  et al. 2004 (65) transfected constructs expressing 
NTF truncations together with the C-terminal fragment (CTF) of PSEN1 into mouse BD8 
cells lacking endogenous Psen1 and Psen2 and saw Notch and APP cleavage activity only for 
truncations with at least 288 amino acid residues (aa) which is nearly the complete NTF. 
Similarly, Kim et al. 2005 (59) saw similar results for Notch cleavage when examining 
truncations of the PSEN1 NTF together with full-length CTF in mouse embryonic fibroblast 
cells (MEFs) lacking Psen1 and Psen2. The different results we obtained for the activity of 
Presenilin truncations in APP cleavage and Notch signalling compared to those above are 
likely because our analysis has examined the expression of truncated PRESENILINs in the 
presence of endogenous gene expression. This illustrates the importance of examining 
dominant mutations in their real, heterozygous state - in the presence of a normal allele – 
rather than in isolation since the activity of the dominant mutation can be dependent on the 
function of the normal allele. Indeed, in our experimental system, when we blocked 
endogenous Psen1 expression in the presence of Psen1Δ>4 we saw that this truncation could 
no longer affect -secretase activity. This is expected since all the truncations except 
Psen1Δ>8 (which includes almost the entire NTF) lack the Asp 257 residue that is thought to 
be essential to the -secretase catalytic site (66). Thus, truncations Psen1Δ>4 and  
P242LfsX11 that both boost Notch signalling must do this by stimulating, (by an unknown 
mechanism/s), the activity of -secretase complexes comprised of normal Presenilin NTFs 
and CTFs. Interaction of truncated Presenilin NTFs with functional -secretase complexes is 
also supported by the data of Kim et al (59) who saw that incorporation of truncated NTFs 
into higher molecular weight complexes was greatest in cells possessing both PSEN1 and 
PSEN2 and was decreased in cells lacking one or both of these genes. For incorporation of 
our truncated forms of Psen1 into higher molecular weight complexes we also observed 
evidence for interactions with endogenous (non-mutant) Presenilin proteins. Future work will 
aim to exploit the FLAG-tagged N-termini of our truncated Psen1 proteins to identify 
interacting proteins by co-immunoprecipitation and proteomics analyses. 
The stimulation of Appa cleavage and Notch signalling by Psen1Δ>4 is consistent with the 
activity of the PS2V isoform that is an equivalent truncation of PSEN2. Forced expression of 
PS2V in mouse neuro 2a cells was seen to increase the production of Aβ peptide consistent 
with an increase in -secretase activity (20). Our observations suggest that PS2V will be 
found to require full-length Presenilin expression for its ability to increase -secretase 
activity. Since Psen1Δ>4 requires endogenous Psen1 but not Psen2 for its activity, it would 
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be interesting to know whether, by analogy, PS2V requires PSEN2 but not PSEN1 (or vice 
versa) to increase Aβ production. 
The G183V mutation of human PSEN1 is remarkable as the only known mutation of this 
gene suggested to produce an exclusively Pick disease FTD phenotype rather than FTD 
associated with AD. Dermaut et al. 2004 (15) showed that the full-length PSEN1 protein 
incorporating the G183V missense mutation did not cause a greatly increased level of Aβ42 to 
Aβ40 production when transfected into HEK293 cells although total levels of Aβ production 
were not reported. This was consistent with brain histopathology showing Pick bodies and 
western analysis showing no detectable Aβ. In a comment on unpublished research regarding 
putative truncated PSEN1 from the aberrant transcript splicing caused by G193V, Dermaut et 
al. 2005 (16) noted that, “cellular gamma-secretase assays show that the truncated proteins 
behave as complete null alleles”. However, no information was given on the cellular system 
used or whether endogenous full-length PSEN1 was present. Watanabe et al. (17) engineered 
the G183V mutation of human PSEN1 into the mouse Psen1 gene and observed aberrant 
splicing of Psen1 transcripts. However, the aberrant splicing was only observed in the brain 
and not other tissues. In the mouse brain, homozygosity for the G183V mutation reduced the 
levels of the normally spliced transcript by approximately half. (In humans, heterozygosity 
for G183V rather than homozygosity presumably means that the reduction in transcript levels 
would be less.) These researchers suggested that reduced -secretase activity in the brain may 
be responsible for the Pick’s disease phenotype and noted that levels of Aβ are, unexpectedly, 
reduced by more than half in cell-free assays conducted using mouse brain. Their results 
supported that the reduction was due to the lower level of PSEN1 protein rather than the 
G183V mis-sense mutation of the coding sequence since G183V mutant PSEN1 protein had 
similar activity to wild type PSEN1 in transfected murine embryonic fibroblasts (MEFs) 
lacking endogenous Presenilin activity. When the same cells were transfected with a 
truncation after exon 5 sequence of the Psen1 open reading frame, Watanabe et al. saw no -
secretase activity. However, if we assume that our observations of Psen1Δ>5 activity in the 
presence of endogenous, normal Presenilin are valid this explains some apparently anomalous 
observations (below). 
In our 2008 paper (32) we showed that a low levels of aberrantly splicing could, nevertheless, 
have potent dominant phenotypes. Thus, we should not assume that the low levels of 
Psen1Δ>5-like transcripts generated by aberrant splicing in the G183V mutant carriers have 
no effect. Indeed, the analyses described in this paper show that Psen1Δ>5 truncated protein 
is notable for its avid incorporation into very stable higher molecular weight complexes and 
its ability to bind full-length forms of Psen1 and Psen2. This may explain why Watanabe et 
al. saw ~50% reductions in both Psen1 transcript levels and Notch cleavage in their 
homozygous mutant mice but considerably more than a 50% reduction in Aβ40 production 
(for Notch and Aβ synthesis measured by cell-free assays on mouse cortex). Also, the idea 
that FTD might be due to a reduction of human PSEN1 transcript levels is not consistent with 
the absence of any reports of FAD in the FAI mutant family bearing the P242LfsX11 
mutation. These individuals show ~50% reduction in wild type PSEN1 transcript levels. This 
reduction presumably occurs in all cells of these individuals since it appears to be due to a 
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frameshift mutation affecting all the transcript products of the mutant allele. Also, aberrant 
PSEN1 transcript splicing has been observed in sporadic FTD brains (30) and, apparently,  
for the L113P FAD mutation of PSEN1 with features of FTD (67). Therefore, we suggest that 
truncated PSEN1 proteins, and in particular truncations similar to Psen1Δ>5, may play a 
decisive role in the development of FTD pathology where PSEN1 gene activity is involved. 
Whether Psen1Δ>5-like truncations perform this role via their effect on APP cleavage or by 
effects on other PRESENILIN activities (such as autophagy, Ca2+ transport or -catenin 
phosphorylation) or via yet unknown activities not dependent on full-length PRESENILINs 
remains to be seen. We can begin to investigate this by analysing the higher molecular weight 
complexes into which Psen1Δ>5 becomes incorporated. 
In zebrafish embryos, suppression of Appa cleavage by Psen1Δ>5 was accompanied by an 
apparent dependence on endogenous Psen1 for complex formation but Psen1Δ>5 had no 
effect on Notch signalling. This would be consistent with Notch and APP cleavage being 
performed by different forms of -secretase complex and/or in different locations within the 
cell. There is experimental data to support both of these ideas since -secretase complexes 
comprised of different isoforms of Aph1 appear to show different proclivities to cleave Notch 
and APP (57) and Notch is thought to be cleaved by -secretase in a process involving 
endocytosis (reviewed by (68)) while cleavage of APP by -secretase has been observed to be 
predominantly in the mitochondrial associated membranes (MAM, (13)). Once again, it will 
be interesting to pursue the identity of the proteins observed to bind so strongly to Psen1Δ>5 
since these may reveal more about the differential cleavage of -secretase substrates. 
The Psen1Δ>6 and Psen1Δ>7 mutations both inhibited Notch signalling but did not affect 
cleavage of Appa. However, the idea that these truncations might delimit a region of the 
PSEN1 NTF within which any truncation could dominantly inhibit Notch signalling was 
refuted by analysis of the truncation produced by the P242LfsX11 FAI mutation. We 
observed that this mutation actually boosted Notch signalling rather than inhibiting it. The 
discoverers of P242LfsX11 noted that levels of PSEN1 transcript are reduced in lymphocytes 
taken from people bearing this mutation (14)). However, the mutant transcript can still be 
detected at low levels (see the supplementary data published with (14)). This is not 
unexpected since the P242LfsX11 mutation generates a frameshift leading to a premature 
termination codon that lies within 20 nucleotides upstream of an exon-exon junction that is 
well within the range defined by the “50-55-bp rule” for inefficient nonsense mediated decay 
(31). Wang et al (14) suggest that the FAI phenotype is due to haploinsufficiency for genes 
encoding components of the γ-secretase complex – i.e. a loss of function phenotype. Our 
result suggests that the effects of these mutations, or at least those of the P242LfsX11 
mutation of PSEN1, may be more complex. The putative loss of Notch signalling caused by 
P242LfsX11 may be less than expected or (depending on the strength of the stimulation) the 
overall level of Notch signalling might possibly be increased. Any other cleavage 
events/pathways mediated by -secretase may be differentially affected compared to Notch. It 
will be informative to investigate the differential effects (if they exist) on -secretase activity 
of FAI mutations in the other components of the -secretase complex. 
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Despite the fact that -secretase activity is known to cleave over 70 different substrates (1) it 
is common to study the effects of Notch signalling using chemical inhibitors of -secretase 
(e.g. (69-71)). One justification for this simplistic approach is that the phenotypes from loss 
of Notch1 or Psen1 in mouse embryos are similar (72, 73) and so facilitation of Notch 
signalling may be the major role of -secretase during embryogenesis. Of course, it would be 
preferable to modulate -secretase activity in a more substrate-specific manner in order to 
dissect its role in development and disease. Our discovery that particular truncations of Psen1 
differentially affects the functions of various -secretase substrates opens the door to a greater 
degree of substrate-specific manipulation of -secretase activity in transgenic animals. It will 
be valuable to investigate the differential effects of our truncations on -secretase substrates 
such as p75, E-cadherin and others. 
 
Materials and Methods 
Zebrafish husbandry and animal ethics 
Wild type zebrafish were maintained in a recirculated water system. All work with zebrafish 
was conducted under the auspices of the Animal Ethics Committee of the University of 
Adelaide.  
Construction of DNAs for expression of truncated zebrafish Psen1 and human PSEN1 
cDNAs encoding Presenilin truncations (including truncations equivalent to the NTF) were 
synthesised by PCR from zebrafish psen1 cDNA or human PSEN1 cDNA. All PCR 
oligonucleotide primer combinations used for constructing cDNAs encoding Presenilin 
truncations are described in Table 1. The zebrafish Psen1 truncations are fused at their N-
termini to a FLAG™ antibody tag,  DYKDDDDK (74) that follows a start codon within a 
consensus Kozak sequence (75). The human PSEN1 truncations are fused at their N-termini 
to an HA tag (YPYDVPDYA (76)) that follows a start codon within a consensus Kozak 
sequence. The cDNA encoding the putative protein product of the P242LfsX11 mutation is 
the human hPSEN1>7 construct into which the P242LfsX11 mutation has been introduced 
by QuikChange™ Site-Directed Mutagenesis (Stratagene Cloning Systems, La Jolla, CA, 
USA). As such, it includes the novel codons found downstream of this frameshift mutation 
before the premature termination codon. The cDNA constructs for synthesis of the negative 
control zebrafish and human mRNAs denoted as “stop” are full length cDNAs including N-
terminal FLAG or HA tag fusions respectively but with codon 4 of the Presenilin coding 
sequences mutated to the stop codon TAA. All sequences were cloned into the pcGlobin2 
vector (62) between the Bam HI and Eco RI restriction sites (for zebrafish cDNAs) and Bam 
HI and Xho I restriction sites (for human cDNAs) and their sequences confirmed by 
sequencing before their use for synthesis of mRNA as previously described (32).  
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Injection of zebrafish embryos 
mRNAs were injected as previously described (32). The morpholino antisense 
oligonucleotides (morpholinos) used in this study and their method of use have been 
described previously (32). In that paper, Morpholino MoPsen1Tln is named MoTln and 
MoPsen2Tln is named MoPS2Tln in (32). The inactive, morpholino, MoCont,  was used as a 
negative control in embryo injections and to dilute the experimental morpholinos above as 
described in (32). 
Western immunoblot analyses of HMW complexes 
At 6 hpf embryos were dechorionated, deyolked and placed in sample buffer (2% sodium 
dodecyl sulfate [SDS], 5% β-mercaptoethanol, 25% v/v glycerol, 0.0625 M Tris–HCl [pH 
6.8], and bromphenol blue), heated immediately at 100°C for 5 min, and then stored at −20°C 
prior to separation on 10% SDS–polyacrylamide gels. Proteins were transferred to 
nitrocellulose membranes using a semidry electrotransfer system. When probed with the anti-
FLAG M2 monoclonal antibody (Sigma, Missouri, USA), the membranes were blocked with 
5% w/v skim milk powder in TBST and then incubated with a 1 in 5,000 dilution of the 
antibody in TBST containing 1% w/v skim milk powder. The membranes were then washed 
four times in TBST and visualized with luminol reagents (Amresco, Ohio, USA) by exposure 
to X-ray films (GE Healthcare LTD, Amersham HyperfilmTM ECL, UK) and the 
ChemiDoc™ MP imaging system (Bio-Rad, Hercules, CA, USA). For incubation with anti-
β-tubulin antibodies (Antibody E7, Developmental Studies Hybridoma Bank, The University 
of Iowa, IA, USA), primary antibodies were diluted to 1 in 200 in TBST containing 1% w/v 
skim milk.  The membranes were then washed in TBST and incubated with a donkey 
antimouse IgG secondary antibody (Jackson ImmunoResearch Laboratories, Inc.) diluted to 1 
in 3,000 in TBST containing 2% w/v skim milk. After incubation with the secondary 
antibody the membranes were washed and visualised in the same fashion as for 
immunoblotting with the anti-FLAG antibody.  
Co-immunoprecipitation analyses 
Embryos at the one-cell stage were injected with mRNA encoding Psen1Δ>5 or an N-
terminally FLAG-tagged GFP molecule. At 6 hpf embryos were dechorionated, deyolked and 
lysed in cell lysis buffer (Sigma, Missouri, USA). For each FLAG-fusion protein sample a 
40l suspension of ANTI-FLAG M2 affinity gel (Sigma, Missouri, USA) was prepared and 
washed with TBS twice.  The samples were incubated with the affinity gel overnight at 4°C 
with gentle mixing. After incubation the affinity gel protein sample mix was washed three 
times with TBS and was left in 10l of sample buffer (2% sodium dodecyl sulfate [SDS], 
25% v/v glycerol, 0.0625 M Tris–HCl [pH 6.8], and bromphenol blue) prior to separation on 
12% SDS–polyacrylamide gels. Proteins were transferred to nitrocellulose membranes using 
a semi-dry electrotransfer system. The membrane was probed with the anti-FLAG M2 
monoclonal antibody (Sigma, Missouri, USA) and the polyclonal antibodies raised against 
Psen1 CTF and Psen2 NTF (previously described in (77)). 
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qPCR 
Embryos at the one-cell stage were injected with mRNAs encoding FLAG-tagged Psen1Δ >6 
or zebrafish Psen1 “stop” negative control. Total RNA was extracted from whole embryos at 
24 hpf using the QAIGEN RNeasy mini kit (QAIGEN, GmbH, Hilden, Germany). Total 
RNA was used to synthesise first-strand cDNA by reverse transcription (Superscript ΙΙΙ kit; 
Invitrogen, Camarillo, USA).  
qPCR for psen1 and ef-1a expression was performed as described previously in Moussavi 
Nik et al. 2012. 
Assays of Notch signalling and Appa cleavage 
Our assay for Notch signalling has previously been described (32) and involves comparison 
of the relative transcription of the Notch target gene neurogenin1 in the trunk region of 
negative control and treated embryos at 24 hpf embryos using in situ transcript hybridisation 
followed by chi-square contingency tests. Increases or decreases in Notch signalling are 
expressed values of p. Smaller values of p may indicate a stronger effect on Notch signalling 
but cannot be interpreted as directly correlated with the magnitude of the loss or gain of the 
signal. Raw data and statistical analysis is given in Supplemental Data Table 1. 
Our assay for γ-secretase cleavage of APP exploits a modified form of zebrafish Appa (see 
Figure 2A) and will be described in detail elsewhere (Wilson et al. manuscript in 
preparation). Briefly, mRNAs encoding a set ratio of “C86” fragment of zebrafish Appa 
fused to destabilised green fluorescent protein (dGFP, see Figure 2A), and free GFP are 
injected into embryos at the one-cell stage. At 12 hpf yolks are removed from embryos. 
These are then lysed and subjected to SDS polyacrylamide gel electrophoresis and western 
immunoblotting with anti-GFP antibody (Rockland Immunochemicals Inc. Gilbertsville, PA, 
USA) for detection of GFP. Variations in relative APP cleavage due to various treatments are 
observed by comparing the C86:dGFP bands on blots after normalising against the free GFP 
bands. The C86:dGFP band intensity was quantified on a Typhoon trio (Amersham 
Bioscience Corp., Piscataway, NJ, USA). Note that the γ-secretase cleavage products of 
C86:dGFP are too unstable to be detected. Assays were completely replicated three times and 
the statistical significance of changes in relative intensity were assessed by one-way ANOVA 
with the Bonferroni Post Hoc test. Raw data and statistical analysis is given in Supplemental 
Data Table 2. 
19 
Acknowledgements 
The β-tubulin (E7) monoclonal antibody was obtained from the Developmental Studies 
Hybridoma Bank developed under the auspices of the NICHD and maintained by The 
University of Iowa, Department of Biology, Iowa City, IA, USA.  
 
Funding 
This work was supported by the Australian National Health and Medical Research Council 
(NHMRC, Project Grant 453622 to ML and RM and Project Grant 1003209 to GC), the 
Cancer Council of South Australia (research grant to ML), The Australian Research Council 
(ARC) Centre for the Molecular Genetics of Development (research funds to ML), the School 
of Molecular and Biomedical Sciences of the University of Adelaide (support of ML and 
MN), the late Douglas Anders (funds to ML), grants from the McCusker Alzheimer’s Disease 
Research Foundation, the Department of Veterans Affairs, and Hollywood Private Hospital 
(to RM), funds from McCusker Alzheimer’s Disease Research Foundation, particularly the 
generous support from Helen Sewell (to GV), Edith Cowan University’s Strategic Research 
Grant (to GV) and the Australian Research Council (Discovery Project Grant DP1094119 to 
GC). We are indebted to Lindsay Carthew for his generous support of MN. 
 
Conflict of Interest Statement 






















































































































































































































































Structure of Presenilin1 protein and truncations. The upper part of the figure shows the 
relationship of psen1 exons to protein structure. Alternating thick and thin areas on the 
protein strand indicate the sequence coded by successive exons (numbered after their cognate 
human exons). Horizontal grey lines indicate the region of the lipid bilayer. “D” indicates the 
position of aspartate residues critical for the catalytic site (shown by a star). The arrowhead 
indicates the site of endoproteolysis that creates the N-terminal fragment (NTF) and C-
terminal fragment (CTF) and the N- and C-termini are indicated. The cytoplasmic loop 
domain and the approximate locations of the G183V mutation putatively causing Pick disease 
and of the P242LfsX11 acne inversa mutation are indicated. Zebrafish Psen1 and human 
PSEN1 truncations were fused at their N-termini to FLAG or HA antibody tags respectively. 
The lower part of the figure shows the putative structure of each truncation of Psen1 and 
summarises their observed effects on Notch signalling and Appa cleavage. ↑indicates 




Assays of relative Notch signalling activity in the presence of truncations of the NTF of 
Psen1. For the Notch assay, comparisons of neurogenin1 expression in the trunk region of the 
developing spinal cord at 24 hpf were made between embryos injected with non-translatable 
Psen1 mRNA (i.e. as the negative control) and embryos injected with mRNAs encoding 
truncations of the NTF of (A) zebrafish Psen1 and (B) human PSEN1 (see Materials and 
Methods and (32)). In A, Psen1>4 stimulates Notch signalling while Psen1>6 and >7 
decrease it. Psen1>5, >8 and non-truncated NTF show no significant effect (ns). In B, the 
same effects are observed for the human PSEN1 truncations. 
 
Figure 3 
Assays of zebrafish Appa cleavage at 12 hpf after injection of mRNAs encoding truncations 
of the NTF of (A) zebrafish Psen1, (B) human PSEN1 or with morpholinos putatively 
generating similar truncations by interference with splicing of endogenous zebrafish psen1 
transcripts (C). The assay measures levels of the Appa C86 fragment that is a substrate for γ-
secretase (see Materials and Methods). In A, Psen1>4 increases Appa cleavage while 
Psen1>5 and the γ-secretase inhibitor DAPT decrease it. Other truncations, the entire NTF 
(NTF) and a negative control mRNA in which codon 4 of the full-length psen1 coding 
sequence is mutated to a stop codon (“stop”) have no significant effect.  Similar effects are 
observed using human PSEN1 truncations in B. In C, morpholino antisense oligonucleotides 
blocking splice acceptor sites are used to interfere with zebrafish psen1 transcript splicing as 
26 
described in (32) putatively resulting in truncated peptides similar to those indicated below 
within parentheses. Not all Psen1 truncations can be created in this way. “5Ac” hybridises to 
the acceptor site of exon 5 etc.. Error bars show standard errors of the means. “-ve*” 
represents embryos injected with the inactive, control morpholino MoCont. **, p < 0.01; ***, 




Zebrafish Psen1Δ>4 acts through endogenous Psen1 to increase Notch signalling and Appa 
cleavage. A, Assays of Notch signalling activity in zebrafish embryos at 24 hpf after injection 
of mRNA encoding either zebrafish Psen1Δ>4 alone (Δ>4), Psen1Δ>4 mRNA with the 
MoPsen1Tln morpholino blocking endogenous Psen1 translation (Δ>4 – Psen1), or 
Psen1Δ>4 mRNA with the MoPsen2Tln morpholino blocking endogenous Psen2 translation 
(Δ>4 – Psen2). For the assay, comparisons of neurogenin1 expression in the trunk region of 
the developing spinal cord at 24 hpf were made against control embryos injected with either 
the MoPsen1Tln or MoPsen2Tln morpholino to block translation of mRNA from the relevant 
endogenous presenilin gene (as indicated) or with an inactive, negative control morpholino 
(all other results). All control embryos were also injected with zebrafish “stop” negative 
control mRNA (see Materials and Methods). B, Assays of Appa cleavage in embryos injected 
with the mRNA encoding the assay substrate and with either zebrafish Psen1Δ>4 mRNA 
alone, Psen1Δ>4 mRNA with the MoPsen1Tln morpholino blocking endogenous Psen1 
translation, Psen1Δ>4 mRNA with the MoPsen2Tln morpholino blocking endogenous Psen2 
translation (Δ>4 – Psen2), with inactive morpholino MoCont only (-ve cont.), or incubated in 
γ-secretase inhibitor DAPT. All assays are conducted relative to embryos injected only with 




Truncations of the Psen1 NTF are incorporated into higher molecular weight complexes. A, 
Embryos were injected with mRNAs encoding the NTF truncations and with either negative 
control morpholino MoCont or with a morpholino suppressing Psen1 translation MoPsen1Tln 
(see lanes marked with *). Embryos were then lysed at 6 hpf and their proteins separated by 
SDS PAGE before immunoblotting with anti-FLAG antibody. Psen1>5 (“>5”) and 
Psen1>8 (“>8”) particularly show decreased formation of two bands/complexes at ~50kDa 
(arrowheads) and increased apparent formation of smaller putative complexes (arrows) and 
higher molecular weight complexes when endogenous Psen1 is reduced. The ~50 kDa 
complexes may include breakdown products of the truncations since their size does not vary 
with the differences in truncation size. However, the specificity of the anti-FLAG antibody 
detection of these complexes is illustrated by their absence when endogenous Psen1 
expression is blocked in embryos with Psen1>5 or Psen1>8 and by the lack of detectable 
staining for injection of the zebrafish negative control mRNA “stop” in which codon 4 of the 
full-length psen1 coding sequence is mutated to a stop codon (“stop”, see Materials and 
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Methods). Ponceau S staining of the blots before antibody exposure confirmed similar 
amounts of total embryo proteins present in each lane (not shown) and this is also illustrated 
by staining for β-Tubulin (β-Tub). B, The constructs coding for zebrafish Psen1 truncations 
include N-terminal FLAG antibody tags allowing co-immunoprecipitation of associated 
proteins. mRNA coding for Psen1>5 (FLAG- Psen1>5)  or for N-terminally FLAG-tagged 
GFP (FLAG-GFP) was injected into zebrafish embryos before lysis under non-denaturing 
conditions at 6 hpf and immunoprecipitation using ANTI-FLAG M2 Affinity Gel. Western 
blotting of the immunoprecipitate revealed binding of endogenous Psen1 and Psen2 proteins 
only to FLAG- Psen1>5 and not to FLAG-GFP. As expected, this procedure conducted on 
uninjected embryos as a negative control showed no co-immunoprecipitated proteins. 
 
Figure 6 
A, Diagram showing the single nucleotide change in exon 7 of human PSEN1 (light grey 
shading) that causes the P242LfsX11 mutation and generates a premature stop codon (dark 
grey shading) within 15 nucleotides of the downstream exon 7 / exon 8 boundary. The novel 
theoretical C terminal of the truncated protein caused by P242LfsX11 is shown in bold text. 
Nucleotide sequence in alternating exons is shown in alternating bold and regular text. 
Codons are indicated using the single amino acid code. Nucleotide and codon numbers are 
derived from ENSEMBL transcript PSEN1-001. B, Assay of zebrafish Appa cleavage at 12 
hpf after injection of mRNA encoding the truncated protein putatively formed by the 
P242LfsX11 mutation. This showed no significant change (ns) relative to a negative control 
in which embryos were injected with mRNA in which codon 4 of the full-length PSEN1 
coding sequence is mutated to a stop codon (“stop”, see Materials and Methods). In contrast, 
the positive control, DAPT treatment, decreased γ-secretase cleavage of Appa (see legend to 
Figure 3 for an explanation). The stop control showed no significant change (ns) relative to 
untreated embryos. Bars show standard errors of the means. C, Assay of relative Notch 
signalling activity (neurogenin1 expression) in the trunk region of the developing spinal cord 
of zebrafish embryos at 24 hpf after injection of mRNA encoding the truncated protein 
putatively formed by the P242LfsX11 mutation. The mutant boosts Notch signalling relative 







 PCR primer and morpholino sequences 
PCR primers Sequence (5′–3′) Amplifies with To form 
zfEx4 GGAATTCTTACTGCTGTCCGTCCTTCTG zfForwardtag  zebrafish  
Psen1Δ>4 
zfEx5 GGAATTCTTACTTGTAGCATCTGTACTT zfForwardtag  zebrafish  
Psen1Δ>5 





























zfTAA zebrafish “stop” 
negative control 























































c725delcforward P242LfsX11 acne 
inversa mutation 
Morpholinos Sequence (5′–3′) Function 
MoCont CCTCTTACCTCAGTTACAATTTATA Negative control morpholino 
MoPsen1Tln ACTAAATCAGCCATCGGAACTGTGA Inhibits endogenous Psen1 translation 
MoPsen2Tln GTGACTGAATTTACATGAAGGATGA Inhibits endogenous Psen2 translation 
MoPsen15Ac GGTGTAGATCCTGCAGAAAAGAAGA Inhibits transcript splicing to the 
acceptor site of exon5 
MoPsen16Ac GCTTGAATCACCTGCAAAAAACAAA Inhibits transcript splicing to the 






AD Alzheimer’s disease 
APH1A 
ANTERIOR PHARYNX DEFECTIVE 1, C. ELEGANS, 
HOMOLOG OF, A 
APP AMYLOID BETA A4 PRECURSOR PROTEIN 
ARC Australian Research Council 
CMV cytomegalovirus 
CTF C-terminal fragment (of a Presenilin protein) 
ER endoplasmic reticulum 
FAD familial Alzheimer’s disease 
FAI familial acne inversa 
FTD frontotemporal dementia 
GFP Green Fluorescent Protein 
HA Haemagglutinin 
HMW high molecular weight 
hpf hours post fertilisation 
kDa kiloDaltons 
MAM mitochondrial associated membranes 
morpholino morpholino antisense oligonucleotide 
NHMRC National Health and Medical Research Council (of Australia) 
NTF N-terminal fragment (of a Presenilin protein) 
PAGE polyacrylamide gel electrophoresis 
PSEN1,2 / PSEN1,2 human PRESENILIN1,2 gene / PRESENILIN1, 2 protein 
psen1,2 / Psen1,2 zebrafish presenilin1,2 gene / Presenilin1,2 protein 
PSENEN PRESENILIN ENHANCER 2, C. ELEGANS, HOMOLOG OF 
TBST Tris Buffered Saline with Tween buffer 
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